Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000216382 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies.
Front Immunol
December 2024
Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States.
Introduction: Immunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a safe and antigen-specific manner.
Methods: To mitigate immunogenicity of monoclonal antibodies administered subcutaneously, O-phospho-L-serine (OPLS)-the head group of the tolerance-inducing phospholipid, phosphatidylserine-was investigated as an immunoregulatory adjuvant.
Results: Formulations of adalimumab, trastuzumab or rituximab with OPLS showed reduction in relative immunogenicity in mice compared to vehicle formulations, indicated by reduced anti-drug antibody development and significant reductions in CD138+ plasma cell differentiation in bone marrow.
Intravenous Versus Peribulbar Dexmedetomidine as an Adjunct to Local Anesthetics in Strabismus Surgery: A Randomized, Double-blinded Clinical Trial.
Pain Physician
November 2024
Faculty of Medicine, Aswan University, Aswan, Egypt Aswan University.
Article Synopsis
- The study explored the effectiveness of dexmedetomidine as an enhancer of peribulbar anesthesia in strabismus surgery, focusing on different administration methods.
- Patients were divided into two groups: one received intravenous dexmedetomidine and the other an injection at the peribulbar site, with various metrics evaluated including pain relief duration and satisfaction.
- Results showed that the peribulbar group experienced longer postoperative analgesia (3.2 hours more) and reported greater satisfaction compared to the intravenous group, indicating that peribulbar dexmedetomidine may be the superior option for enhancing pain management in this context.
A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer.
Clin Breast Cancer
October 2024
Department of Solid Tumor Oncology and Investigational Therapeutics, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC. Electronic address:
Therapy directed against human epidermal growth factor receptor type 2 (HER2) is the standard of care for patients with early-stage and metastatic HER2-positive breast cancer. Treating patients with HER2-positive breast cancer with anti-HER2-monoclonal antibodies, specifically trastuzumab and pertuzumab, is considered standard of care in the neoadjuvant and adjuvant settings and in the first-line setting for metastatic HER2-positive breast cancer. Pertuzumab and trastuzumab are commonly administered intravenously.
View Article and Find Full Text PDFThe combined effect of hypoxia activation and radiosensitization by a multifunctional nanoplatform system enhances the therapeutic efficacy of chemoradiotherapy in pancreatic cancer.
Pancreatology
December 2024
Department of General Surgery, Fujian Medical University Union Hospital, No.29, Xinquan Road, Fuzhou, 350001, China. Electronic address:
Background: Pancreatic cancer is a highly malignant tumor, which is still a major global health problem. Chemotherapy and radiotherapy are regularly used in adjuvant therapy for pancreatic cancer but their therapeutic efficacy is limited.
Methods: In the present study, nanoparticle（MSN-AuNPs） was used as a drug carrier loaded with tirapazamine(TPZ) and hyaluronic acid (HA) to synthesize a multifunctional nanoplatform HA@TPZ-MSN-AuNPs (HTMA) for hypoxia activation and radiotherapy sensitization, which can be combined with radiotherapy therapy and synergistically enhance the therapeutic effect in pancreatic cancer.
Resolution of Vascular Compromise From Liquid Rhinoplasty Using Therapy.
Aesthet Surg J Open Forum
August 2024
Hyaluronic acid (HA) fillers are a relatively safe and effective means of cosmetic treatment for the face; however, as the numbers of both patients and injectors continue to rise, reports of adverse events (AEs) and ischemia are increasing. Although visual complications and stroke are the most-feared AEs, skin and underlying tissue necrosis is far more common and can be catastrophic. HA can be dissolved with hyaluronidase, but this does not always resolve ischemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!